Mometasone Furoate Cream Reduces Acute Radiation Dermatitis in Head and Neck Squamous Cell Carcinomas' Patients
NCT ID: NCT02495064
Last Updated: 2016-03-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
160 participants
INTERVENTIONAL
2015-01-31
2016-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Topical Diclofenac for Prevention of Radiation-induced Dermatitis
NCT06905561
Efficacy of Fullerene in Preventing Radiation Dermatitis in Patients With Head and Neck Cancer .
NCT06484166
Rice Bran Supplementation for Radiation-Induced Oral Mucositis in Head and Neck Cancer
NCT07242859
Biafine Cream to Reduce Side Effects of Radiation Therapy in Patients Receiving Treatment for Advanced Head and Neck Cancer
NCT00006481
Intranasal Corticosteroid Spray for Preventing Otitis Media With Effusion After Radiotherapy in Nasopharyngeal Carcinoma
NCT07189572
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
One side of patients' neck will begin to use MF cream from the first day of radiation therapy, while the other side accept no preventive measures.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
HEALTH_SERVICES_RESEARCH
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Mometasone Furoate Cream(MF)
participants will be given conventional Chemoradiotherapy and MF.
MF Brief introduction:
Generic name :Mometasone Furoate Cream. Dosage form:Each gram of Mometasone Furoate Cream contains mometasone furoate, USP in a cream base of hexylene glycol, phosphoric acid, propylene glycol stearate, stearyl alcohol and ceteareth-20, titanium dioxide, aluminum starch octenylsuccinate, white wax, white petrolatum, and purified water.
Dosage:Apply a thin film of Mometasone Furoate Cream to the affected skin areas once daily during radiotherapy.
It is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Mometasone Furoate Cream
One side of patients' neck will begain to use MF cream from the first day of radiation therapy.
Chemoradiotherapy
conventional Chemoradiotherapy only
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mometasone Furoate Cream
One side of patients' neck will begain to use MF cream from the first day of radiation therapy.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* going to have radiotherapy.
Exclusion Criteria
* lactating women,
* infants,
* elderly people with atrophy skin,
* allergic constitution patients,
* the corresponding parts of 5 radiotherapy skin ulceration or infection and
* allergic patients to Mometasone Furoate Cream.
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yao Liao
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yao Liao
Doctor of oncology department in Mianyang Central Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Wang dong
Role: PRINCIPAL_INVESTIGATOR
Health Bureau of Mian Yang
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
oncology department of Mian yang central Hosptial
Mianyang, Sichuan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MianyangCH
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.